September 21, 2026

Novo Nordisk Capital Markets Day, Telix + ITM $2.35B Radiopharmaceutical Merger, Insmed ARIKAYCE Priority Review

Novo sets 2030 goals as shares fall as much as 9%, Telix agrees a $2.35B merger with ITM, and Insmed's ARIKAYCE wins FDA Priority Review.

6 stories · Covering industry, regulatory, clinical-trials

Editor's Note

Monday centered on Novo Nordisk's Capital Markets Day in London. The company set 2030 ambitions of more than five multi-blockbuster launches, more than 60 million patients served, capacity to serve 10 times more people with obesity on oral GLP-1, and 2026-2030 revenue growth in line with industry peers, and it targets more than DKK 150 billion in pipeline sales in 2035. Shares fell as much as 9% during the session, according to BNN Bloomberg, and management laid out a launch sequence of CagriSema early next year followed by standalone cagrilintide and high-dose CagriSema in 2028. Telix Pharmaceuticals agreed to merge with ITM Isotope Technologies Munich for $1.65 billion upfront plus up to $700 million in milestones tied to ITM-11, bringing ITM's lutetium-177, actinium-225, and terbium-161 production into Telix. Insmed's ARIKAYCE filing for MAC lung disease received FDA Priority Review with a January 28, 2027 action date. Cue Biopharma's anti-IgE antibody CUE-221 beat placebo in a Phase 2 chronic spontaneous urticaria trial, PureTech's LYT-200 received Fast Track designation for use with a hypomethylating agent in relapsed/refractory high-risk MDS, and Beacon Therapeutics said its XLRP gene therapy met the primary endpoint of the Phase 2/3 VISTA trial.

Correction (September 23, 2026): This digest was revised to remove claims that could not be traced to a primary source and to replace general source links with specific ones. Corrected facts: ITM-11 is a somatostatin receptor-targeted agent (177Lu-edotreotide), not an antagonist, and Telix's announcement does not mention an FDA rejection; PureTech describes LYT-200 as a fully human antibody (not a humanized IgG4), and its Fast Track covers use with a hypomethylating agent; Beacon plans a rolling BLA submission later in 2026 (not a BLA and MAA in 2027) and cites XLRP prevalence of about 1 in 25,000 males (not 1 in 40,000). Unsourced claims about Novo's U.S. closing decline, its year-to-date loss, Eli Lilly's market share, a 2032 semaglutide patent date, and a ranking of the combined Telix–ITM business were removed.

Industry

Novo Nordisk Capital Markets Day: 2030 Ambitions Include More Than Five Multi-Blockbusters, 60M Patients, and 10× Oral GLP-1 Capacity; Shares Fall as Much as 9%

Novo Nordisk set out its 2030 ambitions at its Capital Markets Day in London on Monday, September 21, 2026: launch more than five multi-blockbusters, run at least five Phase 3 programs in obesity and diabetes and at least five in other therapy areas, serve more than 60 million patients, build capacity to serve 10 times more people with obesity on oral GLP-1, keep a broadly stable operating margin, and deliver 2026-2030 revenue growth in line with industry peers. It also targets more than DKK 150 billion (about $23 billion) in pipeline sales in 2035, and it said the ambitions are not financial guidance. Shares fell as much as 9% and were down 4.7% by 11:24 GMT, BNN Bloomberg reported, as management faced questions on pricing and dealmaking. Management said CagriSema would launch early next year, followed by standalone cagrilintide and high-dose CagriSema in 2028, with zenagamtide planned to launch in oral and injectable forms at the same time; BNN Bloomberg also reported a plan to scale manufacturing tenfold to supply 15 million patients with oral obesity therapies by the end of the decade.

#novo-nordisk #novo #nvo #capital-markets-day-2026 #london-cmd #mike-doustdar-ceo #2030-strategic-ambitions #5-plus-blockbuster-launches #60-million-patients-globally #10x-manufacturing-scale-up #oral-glp-1-15-million-patients #peer-level-cagr #150-billion-dkk-pipeline-sales-2035 #cagrisema-rollout-2027 #zenagamtide-next-generation #glp-1

Industry

Telix Agrees to Merge with ITM Isotope Technologies Munich for $1.65B Upfront Plus Up to $700M in ITM-11 Milestones, Adding Lu-177, Ac-225, and Tb-161 Production

Telix Pharmaceuticals announced late on September 20, 2026 U.S. Eastern time (September 21 in Australia) an agreement to merge with Germany's ITM Isotope Technologies Munich for $1.65 billion upfront on a cash-free, debt-free basis, including 105.8 million Telix shares, plus up to $700 million tied to regulatory approvals and sales milestones. The milestones are linked to ITM-11 (177Lu-edotreotide), a somatostatin receptor-targeted treatment for gastroenteropancreatic neuroendocrine tumors that completed the Phase 3 COMPETE trial and has fully enrolled a second Phase 3 study, COMPOSE. Telix describes ITM as the world's leading supplier of therapeutic radioisotopes and the only producer of globally scaled commercial-grade lutetium-177, with actinium-225 and terbium-161 production as well. The deal needs Telix shareholder and regulatory approvals and is expected to close by the end of fiscal 2026.

#telix-pharmaceuticals #tlx #itm-isotope-technologies-munich #2-35-billion-merger #1-65-billion-upfront #700-million-contingent #itm-11-neuroendocrine-tumor #177lu-edotreotide #lu-177-lutetium-177 #ac-225-actinium-225 #tb-161-terbium-161 #radiopharmaceutical-powerhouse #peptide-radioligand-therapy #peptide-radioligand

Regulatory

FDA Grants Priority Review to Insmed's ARIKAYCE sNDA for MAC Lung Disease Based on Phase 3b ENCORE; PDUFA Date January 28, 2027

Insmed announced on Monday, September 21, 2026 that the FDA granted Priority Review to its supplemental New Drug Application for ARIKAYCE (amikacin liposome inhalation suspension) to treat Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial regimen, with a PDUFA target action date of January 28, 2027. The filing rests on the Phase 3b ENCORE study, which enrolled 425 patients, 82.4% of them with a first MAC infection, and met its primary endpoint and its multiplicity-controlled secondary culture-conversion endpoints. ARIKAYCE's PULMOVANCE liposomal technology delivers amikacin to lung macrophages while limiting systemic exposure. The drug received FDA accelerated approval in 2018 for refractory MAC lung disease and was the first product approved under the Limited Population Pathway for Antibacterial and Antifungal Drugs.

#insmed #insm #arikayce #amikacin-liposome-inhalation-suspension #pulmovance-liposomal-technology #mac-lung-disease #mycobacterium-avium-complex #fda-priority-review #phase-3b-encore #pdufa-january-28-2027 #limited-population-pathway #lpad-first-product #aminoglycoside-antibiotic #non-peptide

Clinical Trials

Cue Biopharma's Anti-IgE Antibody CUE-221 Meets Phase 2 Endpoints in Chronic Spontaneous Urticaria: 54% Complete Hive Resolution at Week 12 vs 11% on Placebo

Cue Biopharma announced on Sunday, September 20, 2026 topline results from a Phase 2 trial in China of CUE-221, a humanized anti-IgE IgG1 monoclonal antibody that the company says also reduces IgE synthesis, in 145 patients with moderate-to-severe chronic spontaneous urticaria. Patients were randomized to one of three CUE-221 doses, placebo, or omalizumab 300 mg every four weeks. At week 12, complete hive resolution (HSS7 of 0) was reached by 54%, 53%, and 43% of patients on the 4, 2, and 1 mg/kg doses, versus 11% on placebo and 41% on omalizumab. There were no treatment-related serious adverse events and no hypersensitivity reactions. Cue, which licensed CUE-221 from Ascendant Health, plans a Phase 2b/3 study in chronic spontaneous urticaria and a Phase 2 study in food allergy.

#cue-biopharma #cue #cue-221 #dual-mechanism-anti-ige-antibody #chronic-spontaneous-urticaria #csu #phase-2-primary-endpoint-met #54-percent-complete-hive-clearance #week-12-endpoint #ascendant-health-license #xolair-omalizumab-competitor #phase-2b-3-planned #food-allergy-phase-2 #non-peptide

Regulatory

PureTech's Anti-Galectin-9 Antibody LYT-200 Receives FDA Fast Track with a Hypomethylating Agent for Relapsed/Refractory High-Risk MDS; Phase 2 STRIDE-MDS Planned

PureTech Health announced on Monday, September 21, 2026 a successful end-of-Phase 1 meeting with the FDA and Fast Track designation for LYT-200 in combination with a hypomethylating agent (HMA) for relapsed/refractory high-risk myelodysplastic syndromes (HR-MDS). LYT-200 is a fully human monoclonal antibody against galectin-9, developed by PureTech's founded entity Gallop Oncology. In the Phase 1b study, 11 efficacy-evaluable patients who received 12 mg/kg LYT-200 with an HMA had an overall response rate of 45.5% and a complete response rate of 27.3%, with no dose-limiting toxicities. The planned Phase 2 STRIDE-MDS trial will randomize about 125 patients 2:2:1 to 12 mg/kg or 7.5 mg/kg LYT-200 with an HMA, or placebo with an HMA; LYT-200 also holds Fast Track designation in acute myeloid leukemia.

#puretech-health #prtc #gallop-oncology #lyt-200 #anti-galectin-9-antibody #fda-fast-track-designation #end-of-phase-1-meeting #relapsed-refractory-hr-mds #higher-risk-myelodysplastic-syndrome #stride-mds-phase-2 #hypomethylating-agent-context #aml-fast-track #non-peptide

Clinical Trials

Beacon Therapeutics' XLRP Gene Therapy Laru-zova Meets Primary Endpoint in Phase 2/3 VISTA: 31.0% High-Dose and 24.1% Low-Dose Patients Gain 15+ Letters of Low-Luminance Vision vs None in Controls

Beacon Therapeutics reported on Monday, September 21, 2026 that the Phase 2/3 VISTA trial of laruparetigene zovaparvovec (laru-zova), an AAV-based gene therapy that delivers full-length RPGR, met its primary endpoint in X-linked retinitis pigmentosa (XLRP). At month 12, 31.0% of high-dose and 24.1% of low-dose patients had at least a 15-letter improvement in low-luminance visual acuity, versus no patients in the untreated control group, in a trial of 85 males aged 12 to 48. Beacon says no other late-stage XLRP trial has met its primary endpoint, and it reported a favorable safety profile with mostly mild-to-moderate ocular adverse events. The company plans a rolling BLA submission later this year and will present more data at the AAO annual meeting on October 10, 2026; it cites XLRP prevalence of about 1 in 25,000 males. Syncona is among Beacon's investors.

#beacon-therapeutics #syncona #sync #laru-zova #aav-rpgr-gene-therapy #x-linked-retinitis-pigmentosa #xlrp #vista-phase-2-3 #31-percent-high-dose-response #24-1-percent-low-dose-response #15-letter-low-light-vision-gain #low-luminance-visual-acuity #ocular-gene-therapy #rolling-bla-2026 #non-peptide